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Clinical Infectious Diseases
B R I E F R E P O R T
Ebola Virus Persistence in Semen
of Male Survivors
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We investigated the duration of Ebola virus (EBOV) RNA and
infectious EBOV in semen specimens of 5 Ebola virus disease
(EVD) survivors. EBOV RNA and infectious EBOV was detect-
ed by real-time RT-PCR and virus culture out to 290 days and
70 days, respectively, after EVD onset.
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Recently, molecular evidence of sexual transmission of Ebola
virus (EBOV) from a male survivor of Ebola virus disease
(EVD) to a female partner that occurred 179 days after EVD
illness onset was reported in Liberia [1]. A semen specimen
from the survivor collected 199 days after illness onset had
detectable EBOV (Zaire ebolavirus species) RNA, and the
virus isolation attempt was negative [1]. This case highlights
the urgency of understanding EBOV persistence in semen
and assessing potential infectiousness to inform the risk of
transmission of EBOV from male survivors to their sexual
partners.
Limited data from testing of semen specimens collected from
a small number of male survivors of previous EBOV associated
EVD outbreaks indicated that EBOV RNA can be detected up
to 101 days after illness onset [2–4]. Recently, detection of
EBOV RNA in semen was reported up to 284 days after illness
onset [5]. However, the longest period from illness onset that
infectious EBOV has been recovered by viral culture of semen
was from a male survivor at 82 days after EVD symptoms began
[2–4].Given these data, it was important to investigate the dura-
tion and infectiousness of EBOV in available semen specimens
voluntarily submitted by a small number of adult male survivors
of EVD in the United States.
METHODS
Semen specimens from 5 survivors who had experienced mod-
erately severe to critical illness with EVD, all of whom received
different investigational therapeutics in addition to supportive
clinical management during their hospitalization [6], were test-
ed after recovery during 2014–2015. These survivors submitted
semen specimens at different times when convenient after re-
covery from EVD for virologic testing at the Centers for Disease
Control and Prevention (CDC) as part of their follow-up clin-
ical management during the post-EVD convalescent period.
Survivors were counseled by their physicians to abstain from
sex or to use condoms until there was no evidence of EBOV
RNA detected. Semen specimens were collected and transport-
ed as soon as possible or maintained at 4 degrees Celsius and
shipped overnight on frozen cold packs to CDC. The majority of
the specimens were processed within 0–3 days; however a few
were processed 5–8 days after collection. Only one specimen
that was collected 290 days post symptom onset was frozen
prior to virus culture. Semen specimens were processed at CDC
under biosafety level 4 (BSL4) conditions. Nucleic acid was ex-
tracted and tested by quantitative reverse-transcription polymer-
ase chain reaction (qRT-PCR) for EBOV nucleoprotein (NP) as
well as an internal cellular control gene (beta 2-microglobulin
(b2m) (Thermo Fisher Scientiﬁc, #4326319E) [7]. The NP
assay has an estimated limit of detection of 400 TCID50/mL
based on several unpublished studies and from a similar per-
formance proﬁle of the NP EUA assay (http://www.fda.gov/
EmergencyPreparedness/Counterterrorism/MedicalCounter
measures/MCMLegalRegulatoryandPolicyFramework/ucm
182568.htm#ebola). Copies per mL that correspond with virus
load cannot be calculated because the assay detects genomic,
antigenomic, and mRNA; therefore, positive and negative con-
trols are performed for each qRT-PCR run, but no standard
curve is generated. Cycle threshold (Ct) values <40 were consid-
ered positive. Interpretation of qRT-PCR results includes
analysis of the Ct values, curves, and the b2m results for each
specimen. Given the specimen type, studies are ongoing to deter-
mine the distribution of the internal control to provide informa-
tion on specimen quality. To detect infectious virus, cell culture
virus isolation was attempted as previously described [2].
RESULTS
The results of EBOV RNA detection in available semen speci-
mens over time from illness onset are shown in Figure 1. EBOV
RNA was detected in semen out to 290 days after symptom
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onset (272 days after the ﬁrst negative blood specimen result)
(Supplementary Table 1). The ﬁrst negative EBOV RNA result
in semen ranged from 222 to 393 days after illness onset. EBOV
was isolated from semen specimens collected from 3 survivors
and out to 70 days after illness onset (34 days after the ﬁrst neg-
ative blood specimen result). The NP Ct values for semen spec-
imens from which EBOV was isolated by viral culture ranged
from 26 to 30 (Supplementary Table 1). (Higher Ct values indi-
cate lower concentration of the target sequence).
DISCUSSION
We describe the detection of EBOV RNA and infectious virus in
semen specimens collected from 5 male patients who were hos-
pitalized for EVD in the United States during 2014 and recov-
ered. EBOV RNA was detected out to 290 days after illness
onset, whereas infectious EBOV was isolated from semen col-
lected out to 70 days after illness onset. This is similar to the
reported timeframe of 82 days for isolating infectious virus
from semen after illness onset in a previous EVD outbreak [2].
Figure 1. Ebola virus nucleoprotein (NP) quantitative reverse-transcription polymerase chain reaction (qRT-PCR) and virus isolation results on semen specimens. Each
diamond represents an independent semen specimen. NP qRT-PCR results are included inside the diamonds and rectangles as either the cycle threshold value or neg for
negative results. Red and black diamonds represent positive and negative virus isolation, respectively. The rectangles denote no virus isolation was attempted. The red dashed
diamond indicates a contaminated isolation attempt and infectious Ebola virus could not be confirmed. The black dashed line signifies the last day post onset of symptoms
when virus was isolated.
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Infection of the testes by EBOV likely occurs through viremia
during acute EVD. EBOV antigens were identiﬁed in seminifer-
ous tubules from one fatal EVD case [8], and inﬂammation was
reported with identiﬁcation of EBOV particles in interstitial
cells, endothelium, and monocytes of testicular tissue of exper-
imentally infected nonhuman primates [9]. EBOV in the testes
may be shielded from the immune response, and therefore ac-
tive viral replication can continue for prolonged periods. Much
more research is needed to understand the pathogenesis and
maintenance of EBOV in immune-privileged organs. The im-
pact of any investigational therapeutics administered during
clinical management of EVD upon EBOV persistence in the tes-
tes during the post-EVD recovery period is unknown, although
the half-life of these experimental therapies is likely far shorter
than the period for which EBOV could be detected in semen
specimens.
Until recently, the World Health Organization (WHO) and
CDC recommended abstinence or condom use for at least
3 months after recovery from EVD [1]. Based upon uncertainty
about the duration of infectious EBOV in semen and concern of
EBOV sexual transmission through exposure to semen of a re-
covered male EVD survivor, WHO now recommends that male
EVD survivors should abstain from sex or practice safe sex with
correct condom use until semen has tested negative twice with at
least a 1-week interval by RT-PCR [10]. Information about the
limitations of the tests should also be discussed when providing
results. WHO also recommends that if semen has not been test-
ed, safe sex should be practiced for at least 12 months after onset
of EVD. CDC recommends that until more information is
known about the persistence of EBOV in semen, contact with
semen from a recovered EVD patient should be avoided [1, 11].
Our ﬁndings are limited by the overall small number of
semen specimens that were submitted for Ebola virus testing
at different time intervals from illness onset. The longevity of
EBOV RNA detection in semen of male EVD survivors requires
further investigation to determine if there is a correlation be-
tween viral RNA detection and infectious virus. It may be
that higher viral loads during the acute phase of the illness
leads to increased seeding of these immune privileged sites
and therefore prolonged presence of both infectious and non-
infectious EBOV. The sensitivity of virus isolation from semen
specimens could be affected by several factors such as storage
time and temperature, host factors, fungal or bacterial contami-
nants, or presence of unknown inhibitors. Efforts were made to
minimize the time from specimen collection to cell culture inoc-
ulation. Processing of a few specimens were delayed because of
transportation issues, but even at day 5 post collection, a positive
isolate was obtained. The case of suspected EBOV sexual trans-
mission 179 days from symptom onset has raised some questions
about the sensitivity of virus isolation [1], but because the speci-
men that tested positive by qRT-PCR and negative by virus
culture was collected 20 days after the suspected transmission
event, it is possible that infectious virus was no longer present
in semen by the time of sampling.
In conclusion, the reported results support previous data sug-
gesting the potential for sexual transmission of EBOV through
semen exposure to a susceptible sexual partner from a recovered
adolescent or adult male EVD survivor out to at least 82 days
after EVD illness onset. Given the case report of suspected
EBOV sexual transmission 179 days after EVD onset [1], the de-
tection of EBOV RNA in semen for 4–6 months after EVD
onset in 43% of survivors in a cross-sectional study [5], and
our ﬁndings, it seems prudent to adhere to theWHO recommen-
dation for male survivors to practice abstinence or safe sex with
condom use for up to 6 months after EVD onset if semen cannot
be tested. Counseling of all adolescent and adult male survivors
and their sexual partners about the potential for sexual transmis-
sion of EBOV through semen exposure is essential. Broader ep-
idemiological and scientiﬁc studies are needed to assess the risk
of sexual transmission of EBOV from semen as well as vaginal
ﬂuid of EVD survivors to their partners, compliance with
WHO and CDC recommendations, and effectiveness of con-
doms to reduce sexual transmission of EBOV.
Supplementary Data
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